NEW YORK, Oct. 4, 2012 /PRNewswire/ -- IntelliCell
BioSciences, Inc. ("Company") (OTCQB: SVFC) announced
today that it has been granted a Research Tissue Banking License by
the New York State Department of
Health.
Dr. Steven Victor, Chairman and
CEO of IntelliCell, stated that "We are very pleased with the
Tissue Banking License from New York State. This brings us
closer to the development of autologous and allogenic stromal
vascular fraction tissue for researchers around the world.
With the vast amount of clinical research being conducted using
adipose derived cellular components, we can fill a supply chain gap
that exists today. This is significant for the Regenerative
Medicine industry and those conducting important research resulting
in better medicine."
Robert J. Sexauer, Executive Vice
President of Clinical Development, added "it has proven very
challenging for universities and other researchers to obtain a
consistent supply of stromal vascular fraction cells due to HIPPA
and other privacy issues. IntelliCell has developed a
patent pending process that utilizes tissue donors as the source
for the vascular adipose tissue that is processed into the cellular
end product. We are happy to make an important contribution
to the advancement of our technology as it moves from research
laboratories and into the clinic".
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using adult
autologous vascular cells (SVC's) derived from the blood vessels in
the adult adipose tissue. IntelliCell Biosciences has developed its
own patent pending protocol to separate adult autologous vascular
cells from adipose tissue without the use of enzymes. IntelliCell
will also be seeking to develop technology-licensing agreements
with technology developers, universities, and international
business entities.
Forward-Looking Statements
Certain statements set forth in this press release constitute
"forward-looking statements." Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "should," "could," "would," "may" or words or expressions
of similar meaning. Such statements are not guarantees of future
performance and are subject to risks and uncertainties that could
cause the company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contacts:
IntelliCell BioSciences, Inc
Contact: Robert J. Sexauer
Phone: 646.576.8706
Email Contact: rsexauer@intellicellbiosciences.com
SOURCE IntelliCell BioSciences, Inc.